Haematology 2018

Conclusions

• Immunochemotherapy has changed the clinical course of NHL • Although there is much interest in chemotherapy free options, these are not without toxicity…chemotherapy is not dead • Dose intensified therapies continue to have a role • Allogeneic transplantation has only a limited role in NHL • Much excitement about CAR-T, but minimal data…limited applicability